MicrofluidX welcomes new board members and scientific advisor

MicrofluidX, a UK-based developer of technologies that streamline the development and deployment of cell and gene therapies, today announces the appointment of two new board members and an additional scientific advisor to support the company as it progresses towards market launch of its unified development and manufacturing platform, the Cyto EngineTM

The addition of these three distinguished leaders in their respective fields, brings a wealth of expertise to the MicrofluidX team, providing insight into the needs of cell and gene therapy manufacturers as well as extensive experience in the development of innovative tools and technologies to help meet the needs of this rapidly growing sector.

The company welcomes:

Tim Fell - Chair
With a 30+ year career in life sciences technology innovation Tim assumes the role of Board Chair. His proven track record in converting innovation into products and building early stage companies into successful commercial organizations will be instrumental in supporting MicrofluidX through its next phase of technology development and commercialization.

Joseph Gentile - Non-Executive Director
Joseph’s wealth of experience building innovative tools and technology companies in the cell and gene therapy and life sciences sectors provides a tremendous addition to the MicrofluidX board. Based in the US, his support, strategic direction, and guidance in this high-value region will be invaluable as the technology progresses to market entry.

Steven A Feldman - Scientific Advisor
As Site Head and Scientific Director for Stanford’s Laboratory for Cell and Gene Medicine and its GMP Manufacturing Facility, Steven is an internationally recognized expert in the development of cell and gene therapies. As a Scientific Advisor, he will provide key guidance in developing and refining the company's cutting-edge technologies.

CEO of MicrofluidX Antoine Espinet says “We are immensely proud to welcome Tim, Joseph and Steven to the MicrofluidX team. Their experience and insights into developing technologies and building companies, as well as the needs of the Cell and Gene Therapy community will be invaluable as we take the Cyto EngineTM from prototype to product.”

More news and updates